ロード中...
Experience with regorafenib in the treatment of hepatocellular carcinoma
Regorafenib is a diphenylurea oral multikinase inhibitor, structurally comparable to sorafenib, which targets a variety of kinases implicated in angiogenic and tumor growth-promoting pathways. Regorafenib was the first agent to positively show significant survival advantage as a second-line therapy...
保存先:
| 出版年: | Therap Adv Gastroenterol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8165525/ https://ncbi.nlm.nih.gov/pubmed/34104211 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17562848211016959 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|